[go: up one dir, main page]

MX2020003224A - Nuclear receptor modulators. - Google Patents

Nuclear receptor modulators.

Info

Publication number
MX2020003224A
MX2020003224A MX2020003224A MX2020003224A MX2020003224A MX 2020003224 A MX2020003224 A MX 2020003224A MX 2020003224 A MX2020003224 A MX 2020003224A MX 2020003224 A MX2020003224 A MX 2020003224A MX 2020003224 A MX2020003224 A MX 2020003224A
Authority
MX
Mexico
Prior art keywords
receptor modulators
nuclear receptor
compounds
variable
useful
Prior art date
Application number
MX2020003224A
Other languages
Spanish (es)
Inventor
Kevin P Cusack
Eric C Breinlinger
Michael E Kort
Maria A Argiriadi
Dominique Potin
Martine Barth
Olivia Poupardin
Laurent Mounier
Adrian D Hobson
Jérôme Amaudrut
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2015/001693 external-priority patent/WO2016198908A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2020003224A publication Critical patent/MX2020003224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compounds of Formula (I), pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.
MX2020003224A 2015-06-09 2017-12-07 Nuclear receptor modulators. MX2020003224A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2015/001693 WO2016198908A1 (en) 2015-06-09 2015-06-09 Ror nuclear receptor modulators
US201562257806P 2015-11-20 2015-11-20
US201662343905P 2016-06-01 2016-06-01

Publications (1)

Publication Number Publication Date
MX2020003224A true MX2020003224A (en) 2020-07-29

Family

ID=56194583

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015980A MX372543B (en) 2015-06-09 2016-06-08 NUCLEAR RECEPTOR MODULATORS.
MX2020003224A MX2020003224A (en) 2015-06-09 2017-12-07 Nuclear receptor modulators.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017015980A MX372543B (en) 2015-06-09 2016-06-08 NUCLEAR RECEPTOR MODULATORS.

Country Status (36)

Country Link
US (4) US10106501B2 (en)
EP (2) EP3636643A1 (en)
JP (4) JP6549735B2 (en)
KR (1) KR20180014433A (en)
CN (1) CN107820494B (en)
AU (3) AU2016276316B2 (en)
BR (1) BR112017026452A2 (en)
CA (1) CA2988502A1 (en)
CL (1) CL2017003147A1 (en)
CO (1) CO2017012594A2 (en)
CR (1) CR20170594A (en)
CY (1) CY1122495T1 (en)
DK (1) DK3307734T3 (en)
DO (1) DOP2017000289A (en)
EC (1) ECSP18001225A (en)
ES (1) ES2774517T3 (en)
HR (1) HRP20200064T1 (en)
HU (1) HUE047988T2 (en)
IL (2) IL256043B (en)
LT (1) LT3307734T (en)
MA (1) MA51556A (en)
MX (2) MX372543B (en)
MY (1) MY193715A (en)
PE (1) PE20230683A1 (en)
PH (1) PH12017502237B1 (en)
PL (1) PL3307734T3 (en)
PT (1) PT3307734T (en)
RS (1) RS59934B1 (en)
RU (1) RU2715897C2 (en)
SG (1) SG10201911849SA (en)
SI (1) SI3307734T1 (en)
TW (2) TW202128619A (en)
UA (1) UA120651C2 (en)
UY (1) UY36716A (en)
WO (1) WO2016200851A1 (en)
ZA (1) ZA201708285B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026561A2 (en) 2015-06-09 2018-08-14 Bayer Pharma Aktiengesellschaft positive allosteric modulators of m2 muscarinic receptor
CR20170594A (en) * 2015-06-09 2018-04-27 Abbvie Inc NUCLEAR RECEIVER MODULATORS
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
JP2019524722A (en) 2016-07-11 2019-09-05 バイエル・ファルマ・アクティエンゲゼルシャフト 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and uses thereof
JOP20190045A1 (en) 2016-09-14 2019-03-14 Bayer Ag Amide-1-aryl-naphthridine-3-carboxylic acid amide compounds are substituted at position 7 and used.
CN108689942B (en) * 2017-04-11 2023-06-09 广东东阳光药业有限公司 Nitrogen-containing bicyclic compound and its preparation method and use
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
CN110483561B (en) * 2019-08-24 2021-07-23 中国科学院兰州化学物理研究所 A kind of synthetic method of alkenyl boronate compound
CN110407863B (en) * 2019-08-24 2021-08-17 中国科学院兰州化学物理研究所 A kind of method for synthesizing alkenyl boronate compound by transfer boronation reaction
CN114436833B (en) * 2021-12-27 2024-12-24 南京红太阳医药研究院有限公司 A method for preparing telmisartan key intermediate 4'-bromomethylbiphenyl-2-carboxylate
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19
WO2024229569A1 (en) * 2023-05-09 2024-11-14 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)
WO2024254218A2 (en) * 2023-06-05 2024-12-12 The Board Of Regents Of The University Of Texas System Non-peptide small molecule fgf14:nav1.6 channel complex protein-protein interaction modulators
CN117263810B (en) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 Method for preparing aniline compound and selective iodo aniline compound by reducing nitrobenzene
CN119241538A (en) * 2024-09-30 2025-01-03 陕西科技大学 A type of triazolopyridine structure compound, synthesis method and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE136026T1 (en) 1990-09-10 1996-04-15 Rhone Poulenc Rorer Int SUBSTITUTED BIZYCLIC ARYL DERIVATIVES WITH SELECTIVE LEUCOTRIEN B4 ANTAGONISTIC EFFECT
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JP3457694B2 (en) 1993-02-04 2003-10-20 第一製薬株式会社 Influenza prophylaxis and treatment
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US6124463A (en) 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
RU2290403C2 (en) 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Vla-4 inhibitors
US20070129334A1 (en) 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
JPWO2003091211A1 (en) 2002-03-28 2005-09-02 住友製薬株式会社 Novel heteroaryl compounds
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
EP1628970A2 (en) 2003-04-30 2006-03-01 The Institutes of Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
SG130192A1 (en) 2003-07-28 2007-03-20 Janssen Pharmaceutica Nv Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
UY28526A1 (en) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
EA200700119A1 (en) 2004-06-24 2007-10-26 Эли Лилли Энд Компани CONNECTIONS AND METHODS OF TREATMENT OF DYSLIPIDEMIA
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
PT1807072E (en) 2004-10-29 2009-02-16 Lilly Co Eli Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007002325A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
FR2890071B1 (en) 2005-08-30 2007-11-09 Fournier Sa Sa Lab NEW INDOLE COMPOUNDS
BRPI0709612A2 (en) 2006-03-15 2011-07-19 Wyeth Corp compound of formula i; method for treating a central nervous system disorder related or affected by the histamine-3 receptor in a patient in need of this treatment; method for h3 receptor inhibition; pharmaceutical composition; and process for the preparation of a compound of formula i
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
MX2010005070A (en) * 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Pyridazinone derivatives as parp inhibitors.
MX2011008276A (en) 2009-02-06 2011-12-14 Elan Pharm Inc Inhibitors of jun n-terminal kinase.
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
NZ598269A (en) 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8466186B2 (en) * 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP6052685B2 (en) 2011-07-25 2016-12-27 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ N- (imidazolidine-2-ylidene) -heterocyclopenta [b] pyridine derivatives as modulators of α2 adrenergic receptors
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
UA111754C2 (en) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт SUBSTITUTED BENZILINDASOLS FOR THE APPLICATION OF BUB1-KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
KR20140077963A (en) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
EP3027603B1 (en) * 2013-08-02 2018-07-18 Pfizer Inc Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016002718A (en) * 2013-09-11 2016-06-08 Hoffmann La Roche KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS.
CN105940002B (en) 2014-02-03 2018-09-25 生命医药公司 Dihydropyrrolopyridine Inhibitors of ROR-γ
DK3207043T6 (en) 2014-10-14 2020-01-20 Vitae Pharmaceuticals Llc DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR GAMMA
CR20170594A (en) 2015-06-09 2018-04-27 Abbvie Inc NUCLEAR RECEIVER MODULATORS

Also Published As

Publication number Publication date
LT3307734T (en) 2020-05-11
CR20170594A (en) 2018-04-27
TW201718482A (en) 2017-06-01
ES2774517T3 (en) 2020-07-21
KR20180014433A (en) 2018-02-08
ECSP18001225A (en) 2018-03-31
MY193715A (en) 2022-10-26
EP3307734B1 (en) 2019-11-27
MX2017015980A (en) 2018-04-20
AU2021232727A1 (en) 2021-10-14
DOP2017000289A (en) 2017-12-29
JP6549735B2 (en) 2019-07-24
EP3636643A1 (en) 2020-04-15
RU2017146835A (en) 2019-07-12
PH12017502237B1 (en) 2023-11-08
MX372543B (en) 2020-03-23
CO2017012594A2 (en) 2018-03-28
BR112017026452A2 (en) 2018-08-14
JP6938737B2 (en) 2021-09-22
EP3307734A1 (en) 2018-04-18
PH12017502237A1 (en) 2018-06-11
SI3307734T1 (en) 2020-03-31
HUE047988T2 (en) 2020-05-28
UA120651C2 (en) 2020-01-10
US20160362370A1 (en) 2016-12-15
HK1248678A1 (en) 2018-10-19
AU2016276316A1 (en) 2017-12-21
RS59934B1 (en) 2020-03-31
AU2020202584A1 (en) 2020-05-07
SG10201911849SA (en) 2020-01-30
JP7235816B2 (en) 2023-03-09
HRP20200064T1 (en) 2020-04-03
IL256043B (en) 2020-05-31
TWI726888B (en) 2021-05-11
US20190055196A1 (en) 2019-02-21
TW202128619A (en) 2021-08-01
PL3307734T3 (en) 2020-05-18
JP2021191774A (en) 2021-12-16
US10106501B2 (en) 2018-10-23
IL256043A (en) 2018-01-31
JP2018521020A (en) 2018-08-02
CL2017003147A1 (en) 2018-06-01
IL274537A (en) 2020-06-30
MA51556A (en) 2020-11-18
ZA201708285B (en) 2020-02-26
CA2988502A1 (en) 2016-12-15
RU2017146835A3 (en) 2019-11-26
RU2715897C2 (en) 2020-03-04
CN107820494A (en) 2018-03-20
CN107820494B (en) 2020-10-16
PE20230683A1 (en) 2023-04-21
CY1122495T1 (en) 2021-01-27
DK3307734T3 (en) 2020-01-27
UY36716A (en) 2017-01-31
AU2016276316B2 (en) 2020-01-23
PT3307734T (en) 2020-02-25
US20230066771A1 (en) 2023-03-02
JP2019178159A (en) 2019-10-17
WO2016200851A1 (en) 2016-12-15
US20210130293A1 (en) 2021-05-06
JP2020189863A (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MX2020003224A (en) Nuclear receptor modulators.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12018501096A1 (en) Modulators of chemokine receptors
MX2016013564A (en) Heterocyclic kinase inhibitors.
EA201791304A1 (en) IZOHINOLINA DERIVATIVES FOR HIV TREATMENT
EA201791305A1 (en) CONDENSED PYRIMIDINES FOR TREATING HIV
EA201692203A1 (en) TANK-BINDING KINAZ INHIBITING COMPOUNDS
NZ754039A (en) Primary carboxamides as btk inhibitors
MX2016011992A (en) Piperidine-dione derivatives.
EA201891024A1 (en) TANK-BINDING KINASE INHIBITOR COMPOUNDS
GEAP201914379A (en) Heteroaryl compounds for kinase inhibition
EA201691272A1 (en) TETRAHYDROPYRIDOPIRASINES AS GPR6 MODULATORS
EA201591805A1 (en) OXABICICLO [2.2.2] ACIDS - MODULATORS GPR120
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
MX2015005735A (en) Dihydropyrazole gpr40 modulators.
MX2015005720A (en) Dihydropyrazole gpr40 modulators.
AU2015339087B2 (en) Trifluoromethyl alcohols as modulators of RORyt
PH12018500282A1 (en) Cgrp receptor antagonists
EA201790687A1 (en) QUINOLINCARBOXAMIDE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA
MX2016015298A (en) Nampt inhibitors and methods.
TN2017000372A1 (en) Tetrahydropyranyl benzamide derivatives
MX380240B (en) PREPARATION OF PIPERIDIN-4-CARBOTHIOAMIDE.
EA201791596A1 (en) PYRAZOL COMPOUNDS
IN2014MU00072A (en)
IN2014MU00001A (en)